Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Byrd, R. B.
Right arrow Articles by Gracey, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Byrd, R. B.
Right arrow Articles by Gracey, D. R.
(Chest. 1974;66:560-567.)
© 1974 American College of Chest Physicians

Treatment of Pulmonary Tuberculosis

Richard B. Byrd Col., USAF, MC, F.C.C.P.1; Peter D. Kaplan Maj, MC1; and Douglas R. Gracey M.D., F.C.C.P.2

1 Department of Pulmonary Disease, USAF Medical Center, Scott, Scott AFB, Illinois
2 Department of Medicine, Northwestern University School of Medicine, Chicago

Major changes have occurred in the management of pulmonary tuberculosis with emphasis on outpatient rather than inpatient therapy. In addition to an effective regimen including at least two antituberculosis drugs, close follow-up is mandatory following an initial phase of patient education. Even recalcitrant patients may be managed as outpatients by using intermittent twice weekly therapy under supervision. Versatility in antituberculosis therapy has been greatly enhanced by the availability of rifampin and ethambutol, two new oral drugs which have little toxicity. The indications for surgery have diminished, with the greatest challenge in therapy remaining with drug resistant disease. Isoniazid secondary chemoprophylaxis in selected situations remains an important tool in preventing active disease.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1974 by the American College of Chest Physicians.